Table 4.
Combined study using participants of Nordic origin
| DR15+ | A2− | ca/coa | OR (95% CI)b | p | AP |
|---|---|---|---|---|---|
| A. OR with 95% CI of developing MS for subjects categorized by HLA-DRB1*15 and HLA-A*02, in total and stratified by smoking status. Attributable proportion due to interaction between HLA-DRB1*15 and HLA-A*02 | |||||
| Total | |||||
| − | − | 991/3192 | 1.0 (–) | ||
| − | + | 1428/2639 | 1.8 (1.6–1.9) | <0.0001 | |
| + | − | 1732/1439 | 3.9 (3.5–4.3) | <0.0001 | |
| + | + | 2114/1131 | 6.1 (5.5–6.8) | <0.0001 | 0.2 (0.1–0.4), p < 0.0001 |
| DR15+ | A2− | ca/coa | OR (95% CI)c | p | AP |
|---|---|---|---|---|---|
| Never smokers | |||||
| − | − | 490/2163 | 1.0 (–) | ||
| − | + | 749/1861 | 1.8 (1.5–2.0) | <0.0001 | |
| + | − | 922/975 | 4.1 (3.6–4.7) | <0.0001 | |
| + | + | 1152/787 | 6.4 (5.6–7.3) | <0.0001 | 0.2 (0.1–0.3), p < 0.0001 |
| DR15+ | A2− | ca/coa | OR (95% CI)c | p | AP |
|---|---|---|---|---|---|
| Current smokers | |||||
| − | − | 501/1029 | 1.0 (–) | ||
| − | + | 679/778 | 1.8 (1.5–2.1) | <0.0001 | |
| + | − | 810/464 | 3.6 (3.1–4.2) | <0.0001 | |
| + | + | 962/344 | 5.8 (4.9–6.8) | <0.0001 | 0.2 (0.1–0.4), p < 0.0001 |
| A2− | Smoking | ca/coa | OR (95% CI)d | p | AP |
|---|---|---|---|---|---|
| B. OR with 95% CI of developing MS for subjects categorized by HLA-A*02 and smoking, in total and stratified by HLA-DRB1*15 status. Attributable proportion due to interaction between HLA-A*02 and smoking | |||||
| Total | |||||
| − | − | 1412/3138 | 1.0 (–) | ||
| − | + | 1311/1493 | 2.0 (1.8–2.2) | <0.0001 | |
| + | − | 1901/2648 | 1.6 (1.5–1.8) | <0.0001 | |
| + | + | 1641/1122 | 3.5 (3.1–3.9) | <0.0001 | 0.2 (0.1–0.3), p < 0.0001 |
| A2− | Smoking | ca/coa | OR (95% CI)c | p | AP |
|---|---|---|---|---|---|
| HLA-DRB1*15 negative | |||||
| − | − | 490/2163 | 1.0 (–) | ||
| − | + | 501/1029 | 2.1 (1.8–2.5) | <0.0001 | |
| + | − | 749/1861 | 1.8 (1.5–2.0) | <0.0001 | |
| + | + | 679/778 | 3.8 (3.3–4.4) | <0.0001 | 0.2 (0.1–0.3), p < 0.0001 |
| A2− | Smoking | ca/coa | OR (95% CI)c | p | AP |
|---|---|---|---|---|---|
| HLA-DRB1*15 positive | |||||
| − | − | 922/975 | 1.0 (–) | ||
| − | + | 810/464 | 1.9 (1.6–2.2) | <0.0001 | |
| + | − | 1152/787 | 1.6 (1.4–1.8) | <0.0001 | |
| + | + | 962/344 | 3.1 (2.7–3.7) | <0.0001 | 0.2 (0.08–0.3), p = 0.002 |
| DR15+ | Smoking | ca/coa | OR (95% CI)e | p | AP |
|---|---|---|---|---|---|
| C. OR with 95% CI of developing MS for subjects categorized by HLA-DRB1*15 and smoking, in total and stratified by HLA-A*02 status. Attributable proportion due to interaction between HLA-DRB1*15 and smoking | |||||
| Total | |||||
| − | − | 1239/4024 | 1.0 (–) | – | |
| + | + | 1180/1807 | 2.1 (2.0–2.4) | <0.0001 | |
| + | − | 2074/1762 | 3.8 (3.5-4.2) | <0.0001 | |
| + | + | 1772/808 | 7.4 (6.7-8.3) | <0.0001 | 0.3 (0.26–0.4), p < 0001 |
| DR15+ | Smoking | ca/coa | OR (95% CI)c | p | AP |
|---|---|---|---|---|---|
| HLA-A*02 positive | |||||
| − | − | 490/2163 | 1.0 (–) | ||
| − | + | 501/1029 | 2.1 (1.9–2.5) | <0.0001 | |
| + | − | 922/975 | 4.1 (3.6–4.7) | <0.0001 | |
| + | + | 810/464 | 7.7 (6.6–8.9) | <0.0001 | 0.3 (0.2–0.4), p < 0.0001 |
| DR15+ | Smoking | ca/coa | OR (95% CI)c | p | AP |
|---|---|---|---|---|---|
| HLA-A*02 negative | |||||
| − | − | 749/1861 | 1.0 (–) | ||
| − | + | 679/778 | 2.2 (1.9–2.5) | <0.0001 | |
| + | − | 1152/787 | 3.6 (3.2–4.1) | <0.0001 | |
| + | + | 344/962 | 7.2 (6.2–8.4) | <0.0001 | 0.3 (0.2–0.4), p < 0.0001 |
aNumber of exposed cases and controls
bAdjusted for age, gender, smoking, and study
cAdjusted for age, gender, and study
dAdjusted for age, gender, HLA-DRB1*15, and study
eAdjusted for age, gender, HLA-A*02, and study